Clinical Significance of an m6A Reader Gene, *IGF2BP2*, in Head and Neck Squamous Cell Carcinoma

Xiaoli Deng¹, Qingshan Jiang², Zhifeng Liu²* and Wen Chen¹*

¹ Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, China, ² Department of Otorhinolaryngology, The First Affiliated Hospital of University of South China, Hengyang, China

The importance of N6-methyladenosine (m6A) in tumor recurrence and prognosis has been recognized in recent years. The role of m6A readers, such as insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), in regulating head and neck squamous cell carcinoma (HNSCC) remains unclear. We, therefore, assessed the prognostic role of IGF2BP2 in HNSCC using openly available data from The Cancer Genome Atlas (TCGA) in conjunction with HNSCC patient sample immunohistochemistry (*n* = 36).

The correlation between *IGF2BP2* expression and clinical characteristics was then examined. The role of IGF2BP2 in prognosis was assessed by Kaplan–Meier curves and Cox analysis. Finally, TCGA data was used to explore possible carcinogenic mechanisms with multi-GSEA (gene set enrichment analysis). Analysis of TCGA data and IHC results revealed that *IGF2BP2* was upregulated in HNSCC tumor tissues, and the expression level was related to the T stage. Simultaneously, Kaplan–Meier curves and Cox analysis indicated that highly expressed *IGF2BP2* correlated with poor prognosis and that *IGF2BP2* was a potential prognostic factor for HNSCC. Gene set enrichment analysis revealed that scavenging and degradation, synthesis and metabolism, cell growth, death and motility, and cancer pathways were differentially enriched in patients with high *IGF2BP2* expression. Our results demonstrate that *IGF2BP2* plays an important role in tumor progression and may serve as an important biological prognostic factor for HNSCC.

Keywords: head and neck squamous cell carcinoma (HNSCC), insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), N6-methyladenosine (m6A), prognostic factor, tumor

INTRODUCTION

The global incidence of head and neck cancers is increasing (Global Burden of Disease Cancer et al., 2015). Head and neck squamous cell carcinoma (HNSCC) accounts for more than 90% of these malignancies and is usually related to smoking and drinking habits. Nevertheless, a few young people with no alcohol and smoking history may develop HNSCC due to HPV infection (Cramer et al., 2019). Despite continuous innovations in HNSCC treatment methods such as surgery, chemoradiotherapy, and immunotherapy, its 5-year survival rate has not improved significantly (Siegel et al., 2018). Therefore, it is of great importance to find specific molecular markers of HNSCC to better understand its progression and develop novel therapies.
N6-methyladenosine (m6A) is the most common modification of eukaryotic mRNA, characterized by methylation of the N6-position of adenosine. The role of m6A in cancer has just begun to be recognized (Deng et al., 2018). Studies have found that methyltransferases (writers), demethylases (erasers), and binding proteins (readers) regulate m6A (Panneerdoss et al., 2018), while insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) acts as a reader (Hu et al., 2019). IGF2BP2 is also an RNA-binding protein (RBP) that serves as a post-transcriptional regulatory factor for mRNA localization, stability, and translational control (Huang et al., 2018). IGF2BP2 imbalance can lead to the occurrence of many diseases, including insulin resistance, obesity, and cancer. At present, IGF2BP2 has been identified as a novel stage-specific biomarker of colorectal cancer progression. However, whether IGF2BP2 could also be a specific marker in HNSCC is yet to be determined.

In the present study, we have evaluated the expression of IGF2BP2 in HNSCC. We have analyzed the relationship between IGF2BP2 expression and clinical features, as well as explored the potential prognostic significance of IGF2BP2 in HNSCC patients. Multi-gene set enrichment analysis (GSEA) was performed to gain further insight into the biological pathways involved in HNSCC pathogenesis related to the IGF2BP2 regulatory mechanism.

**MATERIALS AND METHODS**

**Data Mining and Collection**

The TCGA HNSC data (528 cases, Workflow Type: HTSeq-Counts) was downloaded from the GDC Data Portal of the National Cancer Institute. The dataset contains survival data with clinical information and mRNA expression counts. The samples with missing expression data were excluded from the study. The RNA-Seq gene expression level 3 HTSeq-Counts data of 501 patients with HNSCC and clinical data were retained and further analyzed. According to the database guidelines, the datasets may be used for publication without restriction or limitation.

**Data Analysis**

The acquired data were analyzed using R (v.3.4.3). Logistic regression and the KS test were used to analyze the correlation between the expression level of the IGF2BP2 gene and clinicopathological features. Cox regression and the Kaplan-Meier curve were used to analyze the overall survival of HNSCC patients with different clinicopathological parameters from the data in TCGA. Finally, we compared the correlation between the expression level of IGF2BP2 and the clinical parameters [age (years ≥60/<60), gender (male/female), grade (G1/G2/G3/G4/Gx), stage (I/II/III/IV), local invasion (T1/T2/T3/T4/Tx), lymph node involvement (positive/negative), distant metastasis (M0/M1/Mx), and HPV infection (positive/negative)] related to survival using the multivariate Cox analysis of influencing factors. The cut-off value of IGF2BP2 expression was determined by Cutoff Finder.

**Gene Set Enrichment Analysis**

GSEA is a computational method used to determine statistical differences between two biological expression states in *a priori* defined set of genes (Subramanian et al., 2005). In this study, GSEA generated an ordered list of genes based on the pathways which were related to the expression level of IGF2BP2 and then annotated the significant differences between the high- and low-level expression groups of IGF2BP2. Each gene set was calculated 1,000 times in each analysis. The expression level of the IGF2BP2 gene acts as a phenotypic label. The signaling pathway enrichment analysis of the phenotypes and the results of the multi-GSEA were ranked by their nominal p-value and normalized enrichment score (NES).

---

1. https://portal.gdc.cancer.gov/repository
2. http://molpath.charite.de/cutoff/load.jsp

---

![Workflow graph for this study.](image-url)
Tissue Preparation and Immunohistochemistry

In total, 36 sets of pathological sections of HNSCC were provided by the First Affiliated Hospital of the University of South China. The sections were placed in 10 mM citrate buffer solution (pH = 6.0) and microwaved for 15 min for antigen retrieval. After restoration to 37°C, 3% hydrogen peroxide was added and incubated for 10 min at 37°C to deplete the activity of endogenous peroxidase. The sections were incubated with an anti-IGF2BP2 polyclonal antibody (Catalog number: 11601-1-AP, Proteintech, Wuhan, China) at 4°C for 24 h, with the optimal dilution ratio of 1:100. After rinsing thoroughly with phosphate buffer solution (PBS), the sections were immunohistochemically colored with horseradish peroxidase-labeled goat anti-rabbit polymers. Finally, the positive expression of the IGF2BP2 protein was observed with the incubated chromogenic agent, 3',3'-diaminobenzidine, and the nuclei were counter-stained with Mayer's hematoxylin. The immunohistochemical staining results of the sections were scored by two different experimenters, blindly. When the experimenters scored sections differently, the sections were re-examined by a third experimenter to reach an agreement. Signal strength was scored in the following manner: 0 (no signal), 1 (weak), 2 (strong). The staining distribution score is based on the percentage of positive cells: 0 (0%), 1 (1–50%), and 2 (51–100%).

RESULTS

Clinicopathological Features of the Patients

The workflow graph of this study is summarized in Figure 1. The gene expression and clinical data of the 501 patients were downloaded from The Cancer Genome Atlas (TCGA) database. The detailed clinical features, including TNM staging, HPV infection status, and survival status, are shown in Table 1.

High IGF2BP2 mRNA Expression in HNSCC

The TCGA database provides a unique opportunity to understand the role of IGF2BP2 in HNSCC. We analyzed the differences in the expression of IGF2BP2 between HNSCC tumor tissues and adjacent tissues through differential expression scatter plots and paired difference analyses. As shown in Figure 2A, the expression level of IGF2BP2 was, statistically, higher in HNSCC tumor tissues (p = 5.533e-19) compared to adjacent tissues. As shown in Figure 2B, the expression of IGF2BP2 in paired cancer tissues was also highly statistically significant (p = 3.333e-16). Then, we verified the level of IGF2BP2 protein expression in 36 pairs of HNSCC tumor tissues and adjacent tissues by immunohistochemistry staining and found significant elevated IGF2BP2 expression in terms of density and intensity in HNSCC tumor tissues compared with adjacent tissues (Figures 2C–H).

Correlation Between Clinicopathological Features and IGF2BP2 Expression in HNSCC

The correlation between the clinicopathological features and the expression of IGF2BP2 is shown in Table 2. The expression of IGF2BP2 was highly statistically significant correlated with local invasion (T1–2 vs. 3–4, p = 0.023) and HPV infection (positive vs. negative, p = 0.001).

Correlation Between IGF2BP2 Expression and Survival

To estimate the effect of IGF2BP2 on the prognosis of HNSCC patients, we used the Kaplan-Meier survival analysis and log-rank test to evaluate the correlation between IGF2BP2 expression...
FIGURE 2 | IGF2BP2 is overexpressed in HNSCC. (A) 354 high IGF2BP2 mRNA expression in HNSCC based on TCGA DATA. (B) Paired difference analysis of IGF2BP2 mRNA expression in HNSCC based on TCGA DATA. (C,D) Representative immunohistochemical staining for IGF2BP2 protein in 36 matched HNSCC tissues and corresponding adjacent non-cancerous epithelial tissues. High expression of IGF2BP2 protein in primary HNSCC specimens (200x, 400x). (E,F) Low expression of IGF2BP2 protein in HNSCC specimens (200x, 400x). (G,H) Negative expression of IGF2BP2 in adjacent non-cancerous epithelial tissues (200x, 400x).

TABLE 2 | Correlation between the clinicopathologic characteristics and IGF2BP2 mRNA expressiona (logistic regression).

| Clinical characteristics | Total (N) | Odds ratio in IGF2BP2 expression | p-Value |
|--------------------------|-----------|---------------------------------|---------|
| Age (≥60 vs. <60)        | 501       | 0.935 (0.657–1.331)             | 0.711   |
| Grade (G1–2 vs. G3–4)    | 482       | 1.007 (0.990–1.026)             | 0.41    |
| Stage (I–II vs. III–IV)  | 284       | 1.015 (0.994–1.036)             | 0.169   |
| Local invasion (T1–2 vs. 3–4) | 445 | 1.017 (1.002–1.032)             | 0.023   |
| Lymph nodes (positive vs. negative) | 408 | 1.009 (0.989–1.030)             | 0.369   |
| HPV infection (positive vs. negative) | 103 | 4.800 (1.831–12.580)             | 0.001   |

aCategorical dependent variable, greater or less than the cutoff expression level. Bold values indicate statistically significant, P < 0.05.

and overall survival. The survival of patients with high IGF2BP2 expression was relatively poor (p = 1.438e-5; Figure 3). The subgroup analysis indicated that the patients in the T1–2 group vs. the T3–4 group with a high expression level of IGF2BP2 also had statistically significant poor overall survival (p = 0.009; Figure 4A) but not in the N classification, M classification or clinical stage (Figures 4B–D). Univariate analysis was performed with the variables listed in Table 3. Multivariate analysis with the Cox proportional hazards model indicated that the expression of IGF2BP2 (HR = 1.013, p = 0.028) was a potential prognostic factor for patients with HNSCC (Table 4). Through the forest plot analysis (Figure 5), there are statistically significant linkages between gender (p = 0.019), distant metastasis (p = 0.022), neck lymph node metastasis (p = 0.002), the expression of IGF2BP2 (p = 0.025) and the outcome of HNSCC patients. In general, IGF2BP2 may serve as a reliable and effective independent prognostic biomarker.

GSEA Identifies an IGF2BP2-Related Signaling Pathway

We performed GSEA to identify differentially regulated pathways between groups with high and low expression of IGF2BP2 and determine the activated signaling pathways in HNSCC. We selected results with significant differences in enrichment (FDR < 0.25, NOM p < 0.05) in the MSigDB gene set (c2.cp.kegg.v6.2.symbols.gmt) (Table 5). The most significantly enriched signaling pathways were selected based on the NES. Figure 6 shows that biological clearance and degradation, synthesis and metabolism, cell growth, death and motility, and
cancer pathways were significantly enriched in the group with high expression levels of IGF2BP2.

**TABLE 3** | Univariate cox regression of overall survival and clinicopathologic characteristics in TCGA HNSCCs patients.

| Clinical characteristics (Univariate cox regression) | Hazard ratio | HR (95% CI) | p-value |
|------------------------------------------------------|--------------|-------------|---------|
| Age, years (≥60/ <60)                                 | 1.301        | 0.974–1.738 | 0.075   |
| Gender (male/female)                                  | 1.366        | 1.013–1.841 | 0.041   |
| IGF2BP2 expression (low/high)                         | 1.014        | 1.004–1.025 | 0.007   |
| Grade (G1/G2/G3/G4/Gx)                               | 1.061        | 0.898–1.254 | 0.487   |
| Stage (I/II/III/IV)                                   | 1.382        | 1.148–1.663 | 0.001   |
| Local invasion (T1/2/3/4/Tx)                          | 1.153        | 1.028–1.294 | 0.015   |
| Lymph nodes (positive/negative)                       | 1.164        | 1.071–1.264 | 0.000   |
| Distant metastasis (M0/M1/Mx)                         | 0.974        | 0.751–1.320 | 0.974   |
| HPV infection (positive/negative)                     | 1.808        | 0.519–6.293 | 0.352   |

Bold values indicate statistically significant, \( P < 0.05 \).

**DISCUSSION**

This study illustrated the importance of IGF2BP2, a potential biomarker for the prognosis of HNSCC patients. We found a high expression of IGF2BP2 in HNSCC tumor tissues and verified
TABLE 4 | Multivariate analyses of overall survival and clinicopathologic characteristics in TCGA HNSCCs patients.

| Clinical characteristics (multivariate analyses) | Hazard ratio | HR (95% CI) | p-Value |
|--------------------------------------------------|--------------|-------------|---------|
| Gender (male/female)                             | 1.454        | 1.046–2.020 | 0.026   |
| IGF2BP2 expression (low/high)                    | 1.013        | 1.001–1.026 | 0.028   |
| Stage (I/II/III/IV)                              | 1.032        | 0.726–1.468 | 0.861   |
| Local invasion (T1/2/3/4/Tx)                     | 1.183        | 0.916–1.528 | 0.197   |
| Lymph nodes (positive/negative)                  | 1.147        | 1.025–1.284 | 0.017   |

Bold values indicate statistically significant, P < 0.05.

This result in our laboratory using immunohistochemistry. This is consistent with previous studies of IGF2BP2 in cancers, including colorectal cancer (Wang et al., 2019), gastrointestinal cancer (Zhou et al., 2017), endometrial cancer (Hiramatsu et al., 2016), pancreas cancer (Xu et al., 2019), breast cancer (McMullen et al., 2018), and hepatic carcinoma. We found that the upregulation of IGF2BP2 had some statistical correlation with the T stage, HPV status, and overall survival in HNSCC. These results suggest that targeting IGF2BP2 may provide a novel treatment for HNSCC, especially in cases that are HPV-driven. Most importantly, we inferred that IGF2BP2 expression is an independent prognostic predictor for the survival of HNSCC and may be a promising biomarker for clinical use. Although our analysis of IGF2BP2 expression does not effectively predict disease-free survival (data not shown), it is closely related to the locally advanced neck and lymph node metastasis in HNSCC patients.

Most of the previous research on IGF2BP2 has focused on its role as a retinol-binding protein (RBP) targeting downstream transcription factors to regulate post-transcriptional translational carcinogenesis. In cervical cancer, gastric carcinoma proliferation enhancing transcript 1 (GHET1) regulates AKT/mTOR and Wnt/β-catenin signaling pathways by stabilizing the interaction of E2F6 and IGF2BP2 (Liu et al., 2020). Non-coding genes

FIGURE 5 | Forest Map Analysis of Expression and clinicopathologic characteristics.
TABLE 5 | Gene sets enriched in phenotype high and low.

| MSigDB collection | Gene set name                        | NES  | NOM p-val | FDR q-val |
|-------------------|--------------------------------------|------|-----------|-----------|
| c2.cp.kegg.v6.2.symptoms.gmt | KEGG_ENDOCYTOSIS | 1.718 | 0.010     | 0.145     |
|                   | KEGG_RNA_DEGRADATION                 | 1.806 | 0.012     | 0.173     |
|                   | KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS  | 1.711 | 0.029     | 0.142     |
|                   | KEGG_ALANINE ASPARATE AND GLUTAMATE_METABOLISM | 1.766 | 0.006     | 0.171     |
|                   | KEGG_AMINOACYL_TRNA_BIOSYNTHESIS     | 1.821 | 0.016     | 0.186     |
|                   | KEGG_ARACHIDONIC ACID_METABOLISM     | 1.531 | 0.021     | 0.674     |
|                   | KEGG_GLYCEROPHOSPHOLIPID_METABOLISM  | 1.742 | 0.006     | 0.161     |
|                   | KEGG_HISTIDINE_METABOLISM            | 1.473 | 0.045     | 0.626     |
|                   | KEGG_PURINE_METABOLISM               | 1.576 | 0.028     | 0.166     |
|                   | KEGG_PHOSPHOLIPID_METABOLISM         | 1.670 | 0.024     | 0.129     |
|                   | KEGG_ADHERENS_JUNCTION               | 1.890 | 0.002     | 0.191     |
|                   | KEGG_BASEAL_TRANSRIPTION_FACTORS     | 1.874 | 0.004     | 0.150     |
|                   | KEGG_CELL_CYCLE                      | 1.744 | 0.033     | 0.178     |
|                   | KEGG_REGULATION_OF_ACTIN_CYTOSKELETON | 1.729 | 0.010     | 0.160     |
|                   | KEGG_PATHWAYS_IN_CANCER              | 1.622 | 0.029     | 0.138     |
|                   | KEGG_WNT_SIGNALING_PATHWAY           | 1.937 | 0.000     | 0.204     |
|                   | KEGG_ERBB_SIGNALING_PATHWAY          | 1.710 | 0.013     | 0.132     |
|                   | KEGG_NOTCH_SIGNALING_PATHWAY         | 1.678 | 0.029     | 0.138     |

Gene sets with NOM P < 0.05 and FDR q < 0.25 are considered as significant. FDR, false discovery rate; NES, normalized enrichment score; NOM, nominal.

FIGURE 6 | Enrichment plots from multiple GSEA. (A) Scavenging and degradation: Endocytosis, RNA degradation and ubiquitin mediated proteolysis. (B) Synthesis and metabolism: Alanine aspartate and glutamate metabolism, aminoacyl tRNA biosynthesis, arachidonic acid metabolism glycerophospholipid metabolism, histidine metabolism, purine metabolism, sphingolipid metabolism. (C) Cell growth, death, and motility: adherens junction, basal transcription factors, cell cycle, regulation of actin cytoskeleton. (D) Cancer pathways and Others: ERBB signaling pathway, Notch signaling pathway, pathways in cancer, Wnt signaling pathway.
IGF2BP2 can also target IGF2BP2 directly: the lncRNA HOTAIR inhibits IGF2BP2 and regulates colon cancer growth and invasion (Wu et al., 2018). IGF2BP2 activity can be mediated by mTOR, a major effector downstream of PI3K/AKT signaling (Lai et al., 2016). Additionally, miR-141 directly targets IGF2BP2 and can reduce PI3K/AKT activity and inhibit pancreatic cancer proliferation (Xu et al., 2019).

In recent years, IGF2BP2 has been found to act as a reader of m6a to regulate carcinogenesis progression. Studies in colon carcinoma have shown that METTL3 stabilizes the expression of SOX2 by an m6A-IGF2BP2-dependent mechanism (Li et al., 2019). Decreased m6A methylation levels are important in endometrial cancer, which is highly associated with the AKT signaling pathway (Liu et al., 2018).

IGF2BP2 expression helps maintain tumor stemness (Kessler et al., 2015). P62, an alternate form of IGF2BP2 through alternative splicing, is highly expressed in hepatocellular carcinoma, which presents with the characteristics of stemness and high blood vessel distribution. The stem gene DLK1 is overexpressed in mice that overexpress P62, and tumor formation is more aggressive due to cancer stemness (Kessler et al., 2015). This regulation of tumor stemness may also be related to chemotherapy resistance and lead to tumor recurrence. The downregulation of IGF2BP2 can induce chemosensitivity, similar to the inhibition of the PI3K/AKT signaling pathway (Mu et al., 2015). Interestingly, in the study of esophageal adenocarcinoma, IGF2BP2 was found to be more highly expressed in metastatic lesions than in primary tumors (Barghash et al., 2016).

Through GSEA analysis, we found that the mechanism of IGF2BP2 in HNSCC may also include the Notch signaling pathway, ERBB signaling pathway, catabolism, lipid metabolism, and amino acid metabolism. In conclusion, our study demonstrated that IGF2BP2 is highly expressed in HNSCC tumor tissues and is associated with tumor progression and poor survival. This study provides new and promising insights for subsequent research to elucidate the molecular pathogenesis of HNSCC. Further mechanistic experiments and randomized clinical trials are required to identify the underlying mechanisms and clinical applications for HNSCC patients.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/supplementary material.

AUTHOR CONTRIBUTIONS

The work supported by grants from the Hunan Provincial Health and Family Planning Commission (20201947; B20180186), the Hunan Provincial Natural Science Foundation of China (2019J50547), and the Science and Technology Department of Hunan Province (2017SK50206).

REFERENCES

Barghash, A., Golob-Schwarzl, N., Helms, V., Haybaeck, J., and Kessler, S. M. (2016). Elevated expression of the IG2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma. Oncotarget 7, 49743–49750. doi: 10.18632/oncotarget.10439

Cramer, J. D., Burtness, B., Le, Q. T., and Ferris, R. L. (2019). The changing therapeutic landscape of head and neck cancer. Nat. Rev. Clin. Oncol. 16, 669–683. doi: 10.1038/s41571-019-0227-z

Deng, X., Su, R., Weng, H., Huang, H., Li, Z., and Chen, J. (2018). RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 28, 507–517. doi: 10.1038/s41422-018-0034-z

Lai, B. Q., Che, M. T., Du, B. L., Zeng, X., Ma, Y. H., Feng, B., et al. (2016). Transplantation of tissue engineering neural network and formation of neuronal relay into the transected rat spinal cord. Biomaterials 109, 40–54. doi: 10.1016/j.biomaterials.2016.08.005

Liu, T., Hu, P. S., Zuo, Z., Lin, J. F., Li, X., Wu, Q. N., et al. (2019). METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal cancer. Mol. Cancer 18:112. doi: 10.1186/s12943-019-1038-7

Liu, J., Eckert, M. A., Harada, B. T., Liu, S. M., Lu, Z., Yu, K., et al. (2018). m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 20, 1074–1083. doi: 10.1038/s41556-018-0174-4

Liu, Z., Luo, S., Wu, M., Huang, C., Shi, H., and Song, X. (2020). LncRNA GHET1 promotes cervical cancer progression through regulating AKT/mTOR and Wnt/beta-catenin signaling pathways. Biochim. Biophys. Acta. Rep. 4:BR20191265. doi: 10.1016/j.sbrb.20191265

McMullen, E. R., Gonzalez, M. E., Skala, S. L., Tran, M., Thomas, D., Djomehri, S. I., et al. (2018). CCN6 regulates IGF2BP2 and HMGAA2 signaling in metaplastic carcinomas of the breast. Breast Cancer Res. Treat. 172, 577–586. doi: 10.1007/s10549-018-4960-2

Mu, Q., Wang, L., Yu, F., Gao, H., Lei, T., Li, P., et al. (2015). Imp2 regulates GBM progression by activating IGF2/Pi3K/Akt pathway. Cancer Biol. Ther. 16, 623–633. doi: 10.1080/15384440.2015.1019185

Panneerdoss, S., Edunuri, V. K., Yadav, P., Timilsina, S., Rajamanickam, S., Viswanadhapalli, S., et al. (2018). Cross-talk among writers, readers, and erasers...
of m(6)A regulates cancer growth and progression. Sci. Adv. 4:eaar8263. doi: 10.1126/sciadv.aar8263

Siegel, R. L., Miller, K. D., and Jemal, A. (2018). Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30. doi: 10.3322/caac.21442

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550. doi: 10.1073/pnas.0506580102

Wang, Y., Lu, J. H., Wu, Q. N., Jin, Y., Wang, D. S., Chen, Y. X., et al. (2019). LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol. Cancer 18:174. doi: 10.1186/s12943-019-1105-0

Wu, X. L., Lu, R. Y., Wang, L. K., Wang, Y. Y., Dai, Y. J., Wang, C. Y., et al. (2018). Long noncoding RNA HOTAIR silencing inhibits invasion and proliferation of human colon cancer LoVo cells via regulating IGF2BP2. J. Cell Biochem. doi: 10.1002/jcb.27079 [Epub ahead of print].

Xu, X., Yu, Y., Zong, K., Lv, P., and Gu, Y. (2019). Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway. J. Exp. Clin. Cancer Res. 38:497. doi: 10.1186/s13046-019-1470-y

Zhou, Y., Huang, T., Siu, H. L., Wong, C. C., Dong, Y., Wu, F., et al. (2017). IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol. Cancer 16:77. doi: 10.1186/s12943-017-0647-2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Deng, Jiang, Liu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.